Last $94.50 USD
Change Today +0.64 / 0.68%
Volume 1.3M
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

50 Northern Avenue

Boston, MA 02210

United States

Phone: 617-341-6100

Fax:

ited States. The partial clinical hold was placed on VX-135 in the United States following observation of reversible elevated liver enzymes in patients who received 400 mg of VX-135 in combination with RBV in a Phase 2 clinical trial conducted in Europe. VX-135 in Combination with Daclatasvir The company, in collaboration with Bristol-Myers Squibb (BMS), is evaluating VX-135 in combination with daclatasvir, an NS5A replication complex inhibitor being developed by BMS, in a Phase 2a clinical trial. The company is in discussions with Alios BioPharma, Inc., or Alios, and BMS regarding these data and potential next steps for further evaluation of VX-135 in combination with daclatasvir. Autoimmune Diseases (Rheumatoid Arthritis) VX-509 VX-509 is an investigational oral drug candidate intended to inhibit Janus kinase 3, or JAK3, which is involved in the modulation of a type of white blood cell, referred to as a lymphocyte, that is central to autoimmune disease pathology. The company completed the evaluation of VX-509 in a double-blind, randomized, placebo-controlled 24-week Phase 2b clinical trial. In addition to the Phase 2b clinical trial in RA, the company completed drug-drug interaction studies of VX-509 in healthy volunteers. These studies demonstrate that dosing of VX-509 inhibits CYP3A4 and indicates that dose modification with frequently prescribed medicines (atorvastatin and methylprednisone) or limited concomitant use of certain medications (e.g. oral midazolam) with VX-509 may be required. INFLUENZA VX-787 VX-787 is an investigational drug candidate intended for the treatment of influenza A, which is typically the predominate strain of influenza and includes H1 (pandemic) and H5 (avian) influenza strains. VX-787 aims to treat influenza A through a mechanism that is different from neuraminidase inhibitors. Collaborations The company entered into the collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (CFFT) in 2004 and amended it various times to support research and development activities related to potentiator compounds and corrector compounds, including ivacaftor, lumacaftor and VX-661. It retains worldwide rights to develop and commercialize ivacaftor, lumacaftor, VX-661 and any other compounds discovered during the course of the research collaboration with CFFT and are obligated to pay CFFT tiered royalties ranging from single digits to sub-teens, calculated as a percentage of net sales, on ivacaftor, as well as lumacaftor, VX-661 and any other compounds discovered during the original research term or the research term that began in 2011. The company has a license and collaboration agreement with Alios BioPharma, Inc. (Alios), a privately-held biotechnology company. Pursuant to the agreement, it is collaborating on the research, development and commercialization of VX-135, an HCV nucleotide analogue discovered by Alios. The company has a license, development, manufacturing, and commercialization agreement with Janssen Pharmaceutica NV (Janssen). Under the agreement, the company collaborated with Janssen on the development and commercialization of telaprevir. The company has exclusive commercial rights to telaprevir in North America and led the development program for telaprevir in North America and the Janssen territories. Janssen has exclusive rights to commercialize INCIVO (telaprevir) outside of North America and the Far East. The company has a collaboration agreement with Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe) pursuant to which Mitsubishi Tanabe has a fully-paid license to manufacture and commercialize TELAVIC (telaprevir) to treat HCV infection in Japan and other specified countries in the Far East. Intellectual Property The company holds issued patents and pending patent applications in the United States, and in foreign countries it deems appropriate, claiming intellectual property developed as part of its research and development programs. The company’s intellectual property holdings include U.S. and foreign patent applications covering potentiator compounds and corrector compounds for the CFTR protein, inclu

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $94.50 USD +0.64

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $161.53 USD -1.88
Alkermes PLC $45.18 USD +0.73
BioMarin Pharmaceutical Inc $68.21 USD +1.32
Illumina Inc $177.00 USD +3.98
Jazz Pharmaceuticals PLC $162.30 USD -2.05
View Industry Companies
 

Industry Analysis

VRTX

Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.4x
Price/Book 19.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.